Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Inotiv stock

Learn how to easily invest in Inotiv stock.

Inotiv Inc
- $1.51 ( - 7.22%)

Inotiv Inc is a diagnostics & research business based in the US. Inotiv shares (NOTV) are listed on the NASDAQ and all prices are listed in US Dollars. Inotiv employs 541 staff and has a trailing 12-month revenue of around $427.3 million.

How to buy shares in Inotiv

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NOTV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Inotiv stock price (NASDAQ: NOTV)

Use our graph to track the performance of NOTV stocks over time.

Inotiv shares at a glance

Information last updated 2022-10-02.
Latest market close$20.92
52-week range$9.14 - $60.66
50-day moving average $20.21
200-day moving average $22.37
Wall St. target price$62.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-4.44

Buy Inotiv shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Inotiv stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inotiv price performance over time

Historical closes compared with the close of $20.92 from 2022-10-05

1 week (2022-09-29) 25.34%
1 month (2022-09-06) 2.30%
3 months (2022-07-06) 96.06%
6 months (2022-04-06) -10.41%
1 year (2021-10-06) -33.84%
2 years (2020-10-06) 313.44%
3 years (2019-10-04) 451.98%
5 years (2017-10-06) 1,109.25%

Is Inotiv stock undervalued or overvalued?

Valuing Inotiv stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Inotiv's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Inotiv's EBITDA

Inotiv's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $53.7 million.

The EBITDA is a measure of a Inotiv's overall financial performance and is widely used to measure a its profitability.

Inotiv financials

Revenue TTM $427.3 million
Operating margin TTM 5.76%
Gross profit TTM $30.2 million
Return on assets TTM 2.29%
Return on equity TTM -23.82%
Profit margin -19.54%
Book value $24.06
Market capitalisation $431.3 million

TTM: trailing 12 months

Inotiv share dividends

We're not expecting Inotiv to pay a dividend over the next 12 months.

Inotiv share price volatility

Over the last 12 months, Inotiv's shares have ranged in value from as little as $9.14 up to $60.66. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inotiv's is 2.7127. This would suggest that Inotiv's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Inotiv overview

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally.

Frequently asked questions

What percentage of Inotiv is owned by insiders or institutions?
Currently 26.001% of Inotiv shares are held by insiders and 44.326% by institutions.
How many people work for Inotiv?
Latest data suggests 541 work at Inotiv.
When does the fiscal year end for Inotiv?
Inotiv's fiscal year ends in September.
Where is Inotiv based?
Inotiv's address is: 2701 Kent Avenue, West Lafayette, IN, United States, 47906-1382
What is Inotiv's ISIN number?
Inotiv's international securities identification number is: US45783Q1004

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site